Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Puerto Rico Technology Today.
Press releases published on August 13, 2025
Alora Healthcare Systems Earns ACHC Product Certification for Home Health Software
ATLANTA, GA, UNITED STATES, August 13, 2025 /EINPresswire.com/ -- Alora Healthcare Systems, a leading provider of cloud-based solutions for the home health care and hospice industries, announced today that its Home Health Software has earned Product …
Eightfold AI Recognized as One of HR Executive Magazine’s 2025 Products of the Year
SANTA CLARA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Eightfold AI has been named to the 2025 Products of the Year list by HR Executive Magazine and the HR Technology Conference. This annual competition, widely regarded as a benchmark for innovation and …
Enovix Shareholder Third Reminder: Early Warrant Expiration Price Condition
FREMONT, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX, ENVXW) (“Company” or “Enovix”), a leader in advanced silicon battery technology, today announced that the price of its common stock has exceeded $10.50 for seventeen …
Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update
Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the …
Applied Therapeutics Reports Second Quarter 2025 Financial Results
- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE Phase 2/3 trial of govorestat for the treatment of CMT- …
Quorum Announces Q2 2025 Results Release Date, Conference Call and Webcast Details
CALGARY, Alberta, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Quorum Information Technologies Inc. (TSX-V: QIS) (“Quorum”), a North American SaaS Software and Services company providing essential enterprise solutions that automotive dealerships and Original …
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programs Consummation of acquisition expected …
Astrotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference in September 2025
AUSTIN, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced that Thomas B. Pickens III, Chairman and Chief Executive Officer, and Jennifer Cañas, Chief Financial Officer, will host …
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as …
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and …
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - …
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable …
Orezone Gold Reports Second Quarter 2025 Results
All dollar amounts are in USD unless otherwise indicated and abbreviation “M” means million. VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX/ASX: ORE, OTCQX: ORZCF) (“Orezone” or “Company”) is pleased to report …
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets Alvotech listed on Nasdaq Stockholm Market …
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types …
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- …
Aterian Reports 2025 Second Quarter Financial Results and Provides Guidance for the Second Half of 2025
SUMMIT, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products company, today announced financial results for the second quarter ended June 30, 2025 (“Q2 2025”) and provided net revenue and …
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to …
Odysight.ai Reports Financial Results for The First Half of 2025 and Provides Business Update
OMER, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announces its financial results for the first half of 2025 and …